CIPAN

Cipan increases investment in Vila Franca de Xira with a new antibiotic

Cipan – Companhia Industrial Productora de Antibioticos will exclusively supply the raw material for a new antibiotic that will be launched, in the first quarter of 2019, in the United States. Approved in October by the US authorities, “Nuzyra” is based on omadicicline, which will be produced in the Portuguese industry installed 55 years ago in the Carregado Vala, north of the municipality of Vila Franca de Xira.

To develop this production, Cipan will invest about six million euros in its own unit, a figure that joins the eight million already invested in the factory in the last two years by the Spanish group SUANFARMA, which acquired Cipan in 2016. The Portuguese company, specialized in the manufacture and marketing of active pharmaceutical ingredients, mainly antibiotics, but also other raw materials, is undergoing a growth phase. In 2017 it had a turnover of 19.2 million euros, 7.6 million more than the previous year. And it plans to reach 25 million by 2018.

Héctor Ara, president of the SUANFARMA group, makes a positive assessment  on the acquisition of the Portuguese company, stressing that it has accumulated know-how and is one of the few in the world that has the conditions to produce, simultaneously, pharmaceutical compounds by fermentation and by chemical synthesis. Héctor Aras told PÚBLICO that it is SUANFARMA’s intention to transfer its research center, currently in Barcelona, ​​to Cipan’s facilities.

Read more in source: Publico

Read More
Cipan

Cipan has investments of 14 million

Cipan, Vala do Carregado’s antibiotic-producing company, is benefiting from investments of around 14 million euros. Acquired two years ago by the Spanish group SUANFARMA, the Companhia Industrial Produtora de Antibioticos, created 55 years ago, doubled its number of employees and recorded a large increase in turnover. The company, which received a visit from local authorities and journalists, is preparing to start an investment of 6 million euros in a new unit aimed at the production of Omadacycline. It is a new active ingredient that Cipan will provide exclusively to a US company that has recently been able to validate a new antibiotic, which will be launched in 2019.

In the last two years, the Spanish group has already invested another 8 million euros in the modernization of Cipan’s facilities and in the construction of a new water treatment plant. The Portuguese company, specialized in the manufacture and commercialization of active pharmaceutical ingredients, mainly antibiotics, but also other raw materials, is going through a phase of great growth. It registered in 2017 a turnover of 19, 262 million euros, plus 7, 6 million of the previous year. And it intends to reach a turnover of 25 million euros already in 2018. Héctor Ara, president of the SUANFARMA group, makes a very positive balance on the acquisition of the Portuguese company, emphasizing that it has a lot of accumulated know-how and that it is one of the few industries in the world that has the conditions to produce, simultaneously, pharmaceutical compounds by fermentation and by chemical synthesis . He also pointed out that Cipan is using actually about the 30 percent of its capacity and that it can grow in the coming years. Alberto Mesquita, mayor of Vila Franca de Xira, congratulated the president of SUANFARMA and the Portuguese managers of Cipan for the development achieved by the company in recent years.

SOURCE: Voz Ribatejana

Read More
Minocycline

Increasing Minocycline production

Cipan is increasing its production of Minocycline HCl in 2017. With a production capacity of 30 Ton/year, Cipan has produced small amounts of this product in the last few years. In 2017, we are significantly increasing the output of Minocycline HCl.

Minocycline is a tetracycline antibiotic and therefore fights bacterial infections  in the human body. Minocycline is used to treat many different bacterial infections, such as urinary tract infections, respiratory infections, but mainly skin infections.

Read More